// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























2187 Abstracts

PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE II STUDY

Nicholas Short - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Blinatumomab

GRAFT-VERSUS-HOST DISEASE OFFERS NO GRAFT-VERSUS-LEUKEMIA ADVANTAGE IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AFTER HAPLO-IDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE

Avichai Shimoni - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Cyclophosphamide

REPEATED INFUSIONS OF ESCALATING DOSES OF EXPANDED AND ACTIVATED AUTOLOGOUS NATURAL KILLER CELLS IN MINIMAL RESIDUAL DISEASE-POSITIVE PH+ ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS. A GIMEMA PHASE 1 TRIAL

Giovanni Fernando Torelli - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

L-Tyrosine

IN VIVO PDX CRISPR/CAS9 SCREENS REVEAL MUTUAL THERAPEUTIC TARGETS TO OVERCOME HETEROGENEOUS ACQUIRED CHEMO-RESISTANCE

Anna-Katharina Wirth - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY-DRUG CONJUGATE

Michael Wang - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

monomethyl auristatin E

SECOND-GENERATION CD19 TARGETING TRI-SPECIFIC KILLER ENGAGER DRIVES ROBUST NK CELL FUNCTION AGAINST B CELL MALIGNANCIES

Jeffrey Miller - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Rituximab

EMPLOYING WHOLE GENOME OPTICAL MAPPING TO CHARACTERIZE THE LANDSCAPE OF STRUCTURAL VARIANTS IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

Danielle Brandes - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

ALTERATIONS IN THE GUT MICROBIOME IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH ACUTE LEUKEMIA

Meerim Park - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

N/A

THE POTENTIAL INFLUENCE OF KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR–LIGAND MISMATCH ON THE PROGNOSIS OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA PATIENTS

Zoya Konova - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

N/A

EXTRAMEDULLARY RELAPSE OF ACUTE MYELOID LEUKEMIA AND ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A SINGLE-CENTER EXPERIENCE

Francisca Vasconcelos - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allopurinol

COMPARISON OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION

Rongli Zhang - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

Allopurinol

REAL-LIFE OUTCOMES OF PONATINIB TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) OR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL): 5-YEAR-DATA FROM A BELGIAN REGISTRY

Timothy Devos - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Ponatinib

TWENTY-ONE YEARS' EXPERIENCE OF THE EORTC 58951 PROTOCOL FOR THE TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN THE SOUTH OF TUNISIA

Imen Frikha - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

CD38: A FUNCTIONING TARGET IN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA. LIMITATIONS IN TREATMENT AND DIAGNOSTICS.

Barbora Vakrmanova - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

daratumumab Intravenous

COMPARISON OF NATURAL KILLER CELL RECONSTITUTION AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION DEPENDING ON THE VARIANT OF T-CELL DEPLETION

Zoya Konova - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA DURING COVID-19

Evgeniya Paramonova - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Acute lymphoblastic leukemia

Glucocorticoid

EASIX ASSESSED AT 1 YEAR AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION PREDICTS THE ONSET OF SUBSEQUENT NON-RELAPSE MORTALITY

Rui Takeda - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Allopurinol

A NOVEL BISPECIFIC T CELL ENGAGER (UMG2-CD3) IS EFFECTIVE AGAINST CORTICAL-DERIVED ACUTE LYMPHOBLASTIC LEUKEMIA

Caterina Riillo - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

DIFFERENTIAL IRON HOMEOSTASIS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN VITRO MODELS

Martina Maria Capelletti - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Ferric ammonium citrate

BH3 PROFILING IDENTIFIES SELECTIVE BCL-2 DEPENDENCE OF ADULT EARLY T-CCELL PROGENITOR AND TYPICAL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

Karanpreet Bhatia - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

Venetoclax

Copyright © 2026. QuantiNova All rights reserved